linjc16/ctgov huggingface dataset:
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

Study Overview
=================
Brief Summary
-----------------
Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.

Official Title
-----------------
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment in Patients With Lung Cancer or Melanoma

Conditions
-----------------
Melanoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Procedure: Blood sample
* Procedure: Tumorous biopsy
* Procedure: Healthy material sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cytological or histological diagnosis of SCLC, NSCLC or melanoma Patients age >/= 18 years old Indication of treatment using platinum salts for lung cancer except for patient with NSCLC treated by surgery for whom platinum salts is not indicated If a biopsy is proposed, lesion lust be easily accessible Signed informed consent Exclusion Criteria: Patients unable to follow the protocol Consent refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Experimental arm<br>Blood sample Tumorous biopsy Healthy material sample | Procedure: Blood sample<br>* Optional<br>Procedure: Tumorous biopsy<br>* Optional<br>Procedure: Healthy material sample<br>* Optional<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mutation rate on tumorous material | Assessed at the time of inclusion using tumorous material used for diagnosis | Assessed at the time of inclusion |
Genetics and Mechanisms of Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
The study is aimed at revealing genetic background in rheumatoid arthritis (RA). For that purpose samples of DNA will be collected from 500 RA patients and similar number of controls from whole Slovakia. Variations in several genes associated with RA will be evaluated. The second aim is to assess functional changes in immune cells from selected patients and their evaluation together with genetic background. The project has observational character without any intention to change the treatment of RA patients.

Official Title
-----------------
Rheumatoid Arthritis Susceptibility Genes in Austrian and Slovak Population

Conditions
-----------------
Rheumatoid Arthritis, Leukocytes, Mononuclear, Genetic Association Studies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: rheumatoid arthritis or healthy Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rheumatoid Arthritis<br>Patients with rheumatoid arthritis | |
| Healthy controls<br>Healthy control subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic association | Association of selected single nucleotide polymorphisms with rheumatoid arthritis. | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peripheral blood mononuclear cells reactivity | Reactivity and functional changes of peripheral blood mononuclear cells obtained from patients with rheumatoid arthritis in comparison to healthy controls. | 1 day |
Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
A double blind randomised placebo controlled parallel trial of the effect of fosinopril, an angiotensin converting enzyme inhibitor, on the quadriceps muscle in 80 COPD patients who have quadriceps weakness. Patients will have a baseline assessment including measures of quadriceps strength and endurance and a quadriceps biopsy. Patients with weakness will be randomised to ACE inhibitor or placebo and re-assessed after three months of treatment. The investigators aim to show that ACE-inhibition will alter the IGF-1/AKT/FoXO/atrogene pathways involved in muscle wasting in COPD.

Official Title
-----------------
ACE-inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Drug: Fosinopril
* Other: lactose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient with COPD diagnosed according to GOLD criteria. Exclusion Criteria: Clinically unstable patients (within one month of exacerbation), those with a permanent pacemaker (which is a contraindication to magnetic stimulation), or significant co-morbidity, patients with an accepted indication for ACE inhibition (left ventricular dysfunction, diabetes) or a contraindication such as renovascular disease; creatinine clearance (estimated) <50); hypotension; use of anticoagulants (contra-indication to biopsy) or ACE-I or ATII receptor antagonists. Allergy to ACE-inhibitors. Pregnancy. Patients will not be enrolled within three months of participation in a pulmonary rehabilitation program.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ACE-inhibitor<br> | Drug: Fosinopril<br>* 10mg od<br>|
| Placebo Comparator: Sugar Pill<br> | Other: lactose<br>* placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in phosphorylation of components of the atrogene pathway |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quadriceps endurance assessed non-volitionally |  | 3 months | 
| Effect of ACE-I on quadriceps maximum voluntary contraction force |  | 3 months | 
| Effect of ACE-I on quadriceps bulk (cross-sectional area) |  | 3 months | 
| Effect of ACE-I on systemic inflammation and serum IGF-1 |  | 3 months |
Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.

Official Title
-----------------
Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection

Conditions
-----------------
Age Related Macular Degeneration, Diabetic Retinopathy

Intervention / Treatment
-----------------
* Drug: Acetazolamide
* Drug: Brimonidine tartarate
* Procedure: Anterior chamber paracentesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of age related macular disease or diabetic retinopathy Able and willing to provide informed consent Exclusion Criteria: History of ocular hypertension or glaucoma High Myopes (> 6 spherical diopters) High Hyperopes (> 4 spherical diopters) Pulmonary disease Renal disease Known allergy to any component of the study drug Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br>Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation | |
| Experimental: 2<br>Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection | Drug: Acetazolamide<br>* 250 mg 1 hour before intravitreal injection<br>* Other names: Diamox;|
| Experimental: 3<br>topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection | Drug: Brimonidine tartarate<br>* 1 drop 1 hour before intravitreal injection<br>* Other names: Alphagan;|
| Experimental: 4<br>anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab | Procedure: Anterior chamber paracentesis<br>* Immediately after bevacizumab injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular pressure (mmHg) |  | 1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intraocular pressure, bevacizumab, acetazolamide, brimonidine, anterior chamber paracentesis
Verification of Correct Positioning of a Gastric Tube by Ultrasonography

Study Overview
=================
Brief Summary
-----------------
There are several ways to verify the correct positioning of a gastric tube. Radiography is considered the reference method. The use of ultrasonography could diminish the number of radiographies necessary. The hypothesis of this research is that gastric ultrasonography performed during insertion of the tube is a reliable examination to check the correct positioning of gastric tubes in intensive care.

Official Title
-----------------
Prospective Study to Evaluate Ultrasound Verification of the Correct Position of Gastric Tubes in Intensive Care

Conditions
-----------------
Insertion of a Nasogastric Tube, Intubated Patient, Patients Hospitalized in the Surgery Intensive Care Unit

Intervention / Treatment
-----------------
* Other: ultrasonography
* Radiation: pulmonary radiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, or their persons of trust, in cases of coma or sedated patients) who have given informed oral consent All patients hospitalized in the surgery intensive care unit of Dijon CHU, who are intubated and require a gastric tube Exclusion Criteria: Adults under guardianship, patients under 18 years of age Patients without national health insurance cover Pregnant women Wound or dressing preventing gastric ultrasonography (laparotomy is not an exclusion criterion if the dressing does not prevent ultrasonography being performed) result of the radiographic verification seen before the gastric ultrasonography is done

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patient with insertion of an NGT<br> | Other: ultrasonography<br> <br> Radiation: pulmonary radiography<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of ultrasonography examinations validating the correct insertion of a nasogastric tube (NGT) |  | Day 1 |
Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?

Study Overview
=================
Brief Summary
-----------------
Total proctocolectomy with ileal pouch anal anastomosis is the first choice surgical operation for management of ulcerative colitis and familial adenomatous polyposis. The addition of diverting ileostomy may reduce septic complications. In this randomized study the investigators compare two groups of patients with stapled ileoanal pouch one of them had diverting ileostomy and in the other this step is omitted.

Conditions
-----------------
Ulcerative Colitis, Familial Adenomatous Polyposis

Intervention / Treatment
-----------------
* Procedure: adding diverting ileostomy
* Procedure: omitting diverting ileostomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having total proctocolectomy with ileal pouch anal anastomosis. Exclusion Criteria: hypoalbuminemia prolonged steroid use anemia anastomosis under tension leak with air test bleeding poor vascular supply of anastomosis
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: stapled ileoanal pouch without diverting ileostomy<br> | Procedure: omitting diverting ileostomy<br> <br> |
| Placebo Comparator: stapled ileoanal pouch with diverting ileostomy<br> | Procedure: adding diverting ileostomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
total proctocolectomy with ileal pouch anal anastomosis with and without ileostomy
The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the health-related quality of life of subjects who have Hereditary Multiple Exostoses and to develop a disease specific quality of life survey. The investigators hypothesize that there are a wide range of quality of life experiences for patients with this syndrome.

Detailed Description
-----------------
At the time of recruitment, subjects will be asked to indicate whether they would like to participate in a one-time survey, or are willing to participate in the initial survey plus two additional questionnaire administrations, thereafter, which will be used to develop the disease-specific quality of life (QOL) score. All participants will complete either the SF-36 survey (for adult HME subjects) or the CHQ PF (for parents of children with HME), as applicable, in addition to a blank form with categorical subheadings (such as recreation, social function, etc.), which they will use to address any issues not covered in the standardized questionnaire. Standardized questionnaires will be scored and analyzed. The items listed on the second form will be compiled and reapplied to subjects that indicated interest in extended participation in survey completion. Subjects will be asked to determine which items apply to them and to rank these applicable items in order of importance. The results from this will be used to develop a 30 question, disease-specific questionnaire. The final step will be to readminister this survey, in conjunction with the SF-36 or CHQ PF, and follow up, in two weeks, with a second administration of the aforementioned surveys, in order to test the variability and validity of the disease-specific, health-related, quality of life score.

Official Title
-----------------
The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses

Conditions
-----------------
Exostoses, Multiple Hereditary

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be diagnosed with Hereditary Multiple Exostoses Adult patients or parents of child patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SF-36 score for adults and CHQ PF-50 for children |  | No time frame | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hereditary Multiple Exostoses, Survey, Quality of Life, Hereditary Multiple Exostoses,, also known as Multiple Hereditary Exostoses,, also known as Hereditary Multiple Osteochondromas
Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa

Study Overview
=================
Brief Summary
-----------------
Our aim was to assess the role and usefulness of Hyperbaric oxygen therapy in a long lasting period, assessing its efficacy on rescuing retinal photoreceptors and preserving visual function in retinitis pigmentosa.

Official Title
-----------------
Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa

Conditions
-----------------
Retinitis Pigmentosa

Intervention / Treatment
-----------------
* Procedure: hyperbaric oxygen therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with clearly hereditary RP (we performed to all of them genetic analysis for rhodopsin, and peripherin genes, only 4 patient with ADRP showed point mutation 3 on codon 135 and 1 on codon 347); best corrected visual acuity (BCVA) ≥ 0.50 logMAR; visual field ≥ 3 degree diameter circle; recordable ERG. Exclusion Criteria: Exclusion criteria were: patients with sporadic RP; BCVA ≤ 0.50 logMAR; visual field ≤ 3 degree diameter circle; not recordable ERG.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: hyperbaric oxygen therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Assessment of Duration of Erection With Vardenafil 10 mg

Study Overview
=================
Brief Summary
-----------------
This study assessed the effect of 10mg vardenafil, taken on demand in an 'at home' setting, as compared to placebo (dummy medication with no pharmacological activity), on the duration of erection from the moment when the patient perceived his erection to be hard enough for penetration until withdrawal from the partner's vagina leading to successful completion which may or may not have included ejaculation. The patient used the stopwatch for the above assessments. The efficacy of oral ED treatments is measured by questionnaires and patient diaries.

Official Title
-----------------
A Randomized, Double-blind, Crossover Study to Evaluate the Duration of Erection Following Vardenafil (10mg) Administration for Four Weeks in a Fixed Dose Regimen Compared to Placebo in Males With ED

Conditions
-----------------
Erectile Dysfunction

Intervention / Treatment
-----------------
* Drug: Levitra (Vardenafil, BAY38-9456)
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- Males with erectile dysfunction- Stable heterosexual relationship Exclusion Criteria:- Primary hypoactive sexual desire- History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months nitrate use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Levitra (Vardenafil, BAY38-9456)<br>* 10mg Vardenafil taken orally 1 hour prior to sexual intercourse<br>|
| Placebo Comparator: Arm 2<br> | Drug: Placebo<br>* Matching placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of vardenafil on the duration of erection |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perception of erection to be hard enough for penetration |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Erectile Dysfunction, Vardenafil